NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Zota Health Care Reports Zero Deviation in Utilization of Funds for Q4 FY26
Zota Health Care Limited has confirmed zero deviation in the utilization of proceeds from its various fund-raising activities for the quarter ended March 31, 2026. The company has fully utilized funds from three separate preferential issues for the expansion of its 'DAVAINDIA' project and working capital requirements. Notably, a significant QIP of ₹34,999.99 lakhs raised in December 2025 remains entirely unutilized as of the quarter-end. The Audit Committee and monitoring agency CRISIL have reviewed and confirmed that all expenditures align with the original stated objectives.
முக்கிய அம்சங்கள்
Confirmed zero deviation or variation in the use of proceeds from multiple preferential issues and a QIP.Fully utilized ₹14,325.83 lakhs for the DAVAINDIA project expansion from the initial preferential issue series.Raised ₹34,999.99 lakhs via QIP in December 2025 at ₹1,535 per share, which remains unspent as of March 31, 2026.Allocated ₹12,962.50 lakhs from QIP proceeds specifically for setting up new COCO stores through DHML.Monitoring agency CRISIL Ratings Limited reviewed the fund utilization for the major capital raises.
👀 கவனிக்க வேண்டியவை
Investors should track the deployment of the ₹340 crore QIP proceeds in upcoming quarters, as this capital is earmarked for the next phase of retail store expansion. The lack of deviation indicates disciplined adherence to the company's stated growth strategy.
Zota Health Care FY26 Net Profit Surges 224% to ₹27.9 Cr; Recommends ₹1 Dividend
Zota Health Care reported a stellar performance for the fiscal year ended March 31, 2026, with standalone revenue growing 58% YoY to ₹407 crore. Net profit witnessed a massive surge of 224%, reaching ₹27.9 crore compared to ₹8.6 crore in the previous year. The Board has recommended a final dividend of ₹1 per share (10%) for FY26. Additionally, the company is strengthening its retail footprint by acquiring 39,794 additional shares in its wholly-owned subsidiary, Davaindia Health Mart Limited, through a rights issue.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations jumped 58.2% YoY to ₹40,700.72 Lakhs in FY26.Net Profit for the year grew by 223.8% to ₹2,790.66 Lakhs from ₹861.72 Lakhs in FY25.Board recommended a 10% final dividend of ₹1 per equity share for the financial year 2025-26.Basic Earnings Per Share (EPS) increased significantly to ₹8.48 in FY26 from ₹3.16 in the previous fiscal year.Approved the acquisition of 39,794 equity shares in subsidiary Davaindia Health Mart Limited via rights issue subscription.
👀 கவனிக்க வேண்டியவை
Investors should take note of the robust triple-digit profit growth and the company's continued investment in its Davaindia retail subsidiary. The stock remains a strong candidate for long-term portfolios given the significant improvement in operational margins and earnings visibility.
Zota Health Care Signs Akshay Kumar as Brand Ambassador for UGO Generic Expansion
Zota Health Care has appointed Bollywood actor Akshay Kumar as the brand ambassador for the company and its 'UGO Generic' brand. This strategic move is designed to scale the UGO Generic brand, which aims to onboard approximately 12.5 lakh retail pharmacies across India. The collaboration focuses on enhancing brand trust and visibility in the affordable generic medicine segment. This initiative operates through KMHP Ventures Limited, a wholly-owned subsidiary, and complements Zota's existing Davaindia chain which manages over 2,000 SKUs.
முக்கிய அம்சங்கள்
Akshay Kumar appointed as brand ambassador for Zota and the UGO Generic brand.UGO Generic targets a massive network of ~12.5 lakh retail pharmacies across India.The brand is managed under KMHP Ventures Limited, a wholly-owned subsidiary of Zota.Zota currently manages over 2,000 SKUs through its existing Davaindia pharmacy chain.The move aims to catalyze PAN India expansion and deepen consumer trust in generic medicines.
👀 கவனிக்க வேண்டியவை
Investors should monitor the speed of pharmacy onboarding under the UGO Generic brand and evaluate if the high-profile endorsement translates into significant revenue growth relative to marketing costs.
Zota Health Care Shareholders Approve ₹1,000 Crore Limit for Loans and Investments
Zota Health Care Limited has received shareholder approval via postal ballot for a special resolution to increase the limits for loans, guarantees, and investments. The Board is now authorized to provide financial assistance or acquire securities up to a limit of ₹1,000 Crores, exceeding the standard thresholds under Section 186 of the Companies Act. The resolution was passed with a significant majority, with 97.96% of the votes cast in favor. This enabling resolution provides the company with substantial financial flexibility for future strategic moves.
முக்கிய அம்சங்கள்
Special resolution passed to authorize loans and investments up to an aggregate limit of ₹1,000 CroresThe resolution received 97.96% votes in favor (13,962,666 votes) and 2.04% against (290,844 votes)Total voter turnout represented 41.16% of the total 34,632,587 shares held by 14,154 shareholdersThe approval allows the Board to exceed the statutory limit of 60% of paid-up capital and reserves or 100% of free reservesThe resolution became effective from April 16, 2026, following the conclusion of the e-voting process
👀 கவனிக்க வேண்டியவை
Investors should monitor future corporate actions to see how this ₹1,000 Crore headroom is utilized, as it suggests potential for significant future acquisitions or strategic investments.
Zota Health Care Proposes Doubling Investment Limit to ₹1,000 Crore Amid Proxy Firm Concerns
Zota Health Care has issued a clarification to shareholders following a report from proxy advisory firm IiAS regarding a resolution to increase inter-corporate loan and investment limits. The company is seeking to raise the limit from ₹500 crores to ₹1,000 crores, noting that the previous limit approved in March 2025 has already been exhausted. Management justifies this increase as necessary for supporting the working capital needs of its subsidiary, Davaindia Health Mart, and for potential strategic acquisitions. The company maintains that all transactions will adhere to strict governance frameworks and statutory disclosure requirements.
முக்கிய அம்சங்கள்
Proposed increase in Section 186 limits for loans, guarantees, and investments from ₹500 crores to ₹1,000 crores.The previous ₹500 crore limit approved on March 26, 2025, is already exhausted due to recent QIP-funded investments.A significant portion of the headroom is intended for Davaindia Health Mart Limited, a major revenue contributor.The response addresses concerns raised by Institutional Investor Advisory Services (IiAS) in their report dated March 27, 2026.Voting for this resolution via postal ballot is scheduled to conclude on April 16, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the postal ballot and future disclosures regarding how this ₹1,000 crore limit is utilized, particularly concerning promoter-group entities. While the expansion is growth-oriented, the proxy firm's caution suggests a need for careful oversight of capital allocation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Zota Health Care Seeks Shareholder Approval for ₹1,000 Crore Investment and Loan Limit
Zota Health Care Limited has issued a postal ballot notice to seek shareholder approval for a special resolution under Section 186 of the Companies Act. The company is requesting authorization for the Board to provide loans, guarantees, or acquire securities up to a maximum limit of ₹1,000 Crores. This proposed limit exceeds the standard statutory thresholds of 60% of paid-up capital and reserves or 100% of free reserves. The e-voting period for shareholders is scheduled from March 18, 2026, to April 16, 2026.
முக்கிய அம்சங்கள்
Proposed aggregate limit for loans, guarantees, and investments set at ₹1,000 Crores.Resolution seeks to exceed the standard 60% of paid-up capital/reserves or 100% of free reserves limit.Remote e-voting period spans from March 18, 2026, to April 16, 2026.Final voting results to be declared on or before April 17, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company for upcoming announcements regarding potential acquisitions or strategic investments that would utilize this ₹1,000 Crore headroom. This move signals a possible shift toward aggressive inorganic growth or significant subsidiary funding.
Zota Health Care to Seek Shareholder Approval for Increased Investment and Loan Limits
Zota Health Care's Board has approved a proposal to seek shareholder consent via postal ballot to increase limits for loans, guarantees, and investments under Section 186 of the Companies Act, 2013. This move indicates the company is preparing for potential strategic investments or providing financial support to other entities beyond current statutory limits. The cut-off date for voting eligibility was set for March 13, 2026, with the e-voting period concluding on April 16, 2026. Investors should monitor the specific limit amounts and the intended purpose once the detailed postal ballot notice is released.
முக்கிய அம்சங்கள்
Board approved seeking shareholder approval to exceed Section 186 limits for loans, guarantees, and securities.Cut-off date for determining voting rights for the Postal Ballot is March 13, 2026.E-voting period is scheduled to run from March 18, 2026, to April 16, 2026.Mr. Ranjit B. Kejriwal has been appointed as the Scrutinizer for the voting process.Final results of the postal ballot are expected to be declared by April 17, 2026.
👀 கவனிக்க வேண்டியவை
Investors should review the upcoming Postal Ballot notice to understand the specific financial limits being requested and the company's rationale for potential future investments or loans.
Zota Health Care Launches "All Day Stores" Retail Chain; Plans 50 Outlets in First Phase
Zota Health Care, through its subsidiary Everyday Herbal Beauty Care Limited, is launching a new national retail chain called "All Day Stores" (ADS). The expansion begins with 50 outlets in the first phase, with 15 stores scheduled to open on March 07, 2026, across five Indian states including Gujarat and Maharashtra. Each store will feature over 430 SKUs of private-label products, including personal care and household essentials, in formats ranging from 500 to 1000 square feet. This move represents a strategic forward-integration effort to diversify revenue beyond its existing generic medicine chain, Davaindia.
முக்கிய அம்சங்கள்
Launch of 'All Day Stores' (ADS) retail chain via subsidiary Everyday Herbal Beauty Care LimitedPhase 1 expansion includes 50 outlets, with the first 15 stores opening on March 07, 2026Stores will offer over 430 SKUs of private-label products across personal care, OTC, and essentialsInitial rollout covers key markets in Gujarat, West Bengal, Maharashtra, Karnataka, and DelhiStore sizes optimized between 500 to 1000 square feet to ensure a comfortable shopping experience
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the store rollout and its impact on consolidated margins, as private-label retail typically offers higher profitability than third-party brands. The success of this diversification beyond generic medicines could be a significant long-term value driver for the company.
Zota Health Care Increases Stake in Subsidiary EHBCL to 87.78% for Rs 19.47 Crore
Zota Health Care has significantly increased its ownership in its subsidiary, Everyday Herbal Beauty Care Limited (EHBCL), by acquiring an additional 21.80% stake. The acquisition was executed via a rights issue subscription for a total consideration of Rs 19.47 crore at Rs 16.50 per share. This transaction raises Zota's total shareholding in EHBCL to 87.78%, up from approximately 66%. EHBCL, which manufactures products under the 'Khadi India' brand, showed robust growth with turnover jumping from Rs 73.39 lakhs in FY24 to Rs 1,144.22 lakhs in FY25.
முக்கிய அம்சங்கள்
Acquired 1,18,00,000 equity shares representing a 21.80% stake in subsidiary EHBCL.Total investment of Rs 19.47 crore at an acquisition price of Rs 16.50 per share.Post-acquisition shareholding in EHBCL has increased to 87.78%.EHBCL reported a significant turnover growth to Rs 1,144.22 lakhs in FY 2024-25.The move is intended to strengthen backward integration in the cosmetic, ayurvedic, and OTC segments.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this consolidation of control in a high-growth subsidiary that provides backward integration. Monitor the subsidiary's ability to scale the 'Khadi India' brand and its impact on Zota's consolidated margins.
Zota Health Care Expands Davaindia Network to 2,502 Operational Stores
Zota Health Care has reached a significant milestone with its Davaindia network growing to 2,502 operational stores as of February 11, 2026. This represents a rapid addition of 171 stores since December 31, 2025, when the count stood at 2,331. The current network is comprised of 1,607 Company Owned Company Operated (COCO) stores and 895 Franchisee Owned Franchisee Operated (FOFO) stores. For the current fiscal year, the company has added a total of 920 stores, with a strategic focus on the COCO model which accounted for 755 of those additions.
முக்கிய அம்சங்கள்
Total operational stores reached 2,502 as of February 11, 2026, up from 2,331 in December 2025Added 920 stores in the current fiscal year, including 755 COCO and 165 FOFO unitsCOCO stores now make up the majority of the network with 1,607 operational unitsThe network expansion demonstrates a high execution rate with 171 stores added in approximately 40 daysStrategic focus remains on providing affordable generic medicines through a mix of owned and franchised outlets
👀 கவனிக்க வேண்டியவை
Investors should view this rapid footprint expansion as a positive indicator of scale; however, they should monitor upcoming earnings to see how the increased COCO store count impacts operating margins and capital expenditure.
Zota Health Care Allots 5.71 Lakh Shares; Completes Warrant Conversion Cycle
Zota Health Care has allotted 5,71,961 equity shares to 11 non-promoter investors upon the conversion of the final batch of warrants. The company received Rs. 21.83 Crores as exercise money, representing 75% of the total issue price of Rs. 509 per share. This allotment increases the total paid-up equity capital to Rs. 34.63 Crores. With this conversion, the company has successfully closed the warrant issue initiated in August 2024, with no outstanding warrants remaining.
முக்கிய அம்சங்கள்
Allotment of 5,71,961 equity shares at Rs. 509 per share (including Rs. 499 premium).Infusion of Rs. 21.83 Crores in capital from 11 non-promoter group investors.Total paid-up capital increased from 3.40 Crore to 3.46 Crore equity shares.Zero outstanding warrants remain from the original 26.44 lakh warrant issue.
👀 கவனிக்க வேண்டியவை
The completion of the warrant conversion removes the overhang of future dilution from this specific issue. Investors should monitor how the company utilizes the newly raised capital for growth or debt reduction.
Zota Health Care Q3FY26 Revenue Jumps 98% YoY to ₹143 Cr; Plans 5,000 Stores by 2029
Zota Health Care reported a robust 98.2% YoY revenue growth in Q3FY26, reaching INR 142.95 crore, driven by the aggressive expansion of its Davaindia network. The company added 276 stores during the quarter, bringing the total count to 2,331, while successfully raising INR 350 crore via QIP to fund future growth. Although EBITDA was impacted by pre-operative expenses for approximately 400 stores in the pipeline, management remains confident in reaching 5,000 stores by March 2029. Strategic moves include the acquisition of Curexis and the formation of a new marketing subsidiary to optimize margins.
முக்கிய அம்சங்கள்
Consolidated revenue surged 98.2% YoY to INR 142.95 crore, with Davaindia contributing 80% of total sales.Added 276 new stores in Q3, taking the total Davaindia footprint to 2,331 stores across 23 states and 5 UTs.Successfully completed a INR 350 crore QIP to accelerate the rollout of Company-Owned Company-Operated (COCO) stores.Quarterly customer footfall nearly doubled to 49 lakhs compared to 27 lakhs in the previous year.Acquired 100% stake in Curexis (SKIA brand) and incorporated KMHP Ventures for better sourcing and distribution.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin recovery as the 400+ stores currently under development become operational and start contributing to the bottom line. The successful QIP provides a strong capital cushion for the company's ambitious 5,000-store target by 2029.
Zota Health Care Q3FY26: Davaindia Network Expands to 2,331 Stores; 9M Revenue at ₹375.48 Cr
Zota Health Care reported a consolidated revenue of ₹37,548 lakhs for 9MFY26, with its Davaindia retail chain contributing 73% of the total. The company has aggressively expanded its retail footprint to 2,331 stores, focusing on the more profitable COCO (Company-Owned Company-Operated) model which now stands at 1,438 units. Strategic integration through a 65.98% stake in Everyday Herbal Group and a growing export portfolio of 325 approved products highlight diversified growth. The business model focuses on providing generic medicines at 30-90% lower costs than branded competitors.
முக்கிய அம்சங்கள்
9MFY26 Consolidated Revenue stood at ₹37,548 lakhs with a Gross Profit of ₹22,113 lakhs.Davaindia retail network reached 2,331 active stores, including 1,438 COCO and 893 FOFO outlets.Davaindia segment dominates the revenue mix at 73%, followed by Domestic Marketing at 15%.Export operations have 325 product approvals across 30+ countries, with 586 total dossier applications.Strategic backward integration completed with a 65.98% stake in Everyday Herbal Group for OTC expansion.
👀 கவனிக்க வேண்டியவை
Investors should track the margin improvement as the company shifts towards the COCO model and scales its OTC portfolio. The aggressive retail expansion positions Zota as a key player in the affordable healthcare segment.
Zota Health Care Q3FY26 Revenue Surges 98.2% YoY to ₹142.95 Cr; Store Count Hits 2,331
Zota Health Care reported a massive 98.2% YoY revenue growth in Q3FY26, reaching ₹14,295.14 lakhs, primarily driven by the rapid expansion of its Davaindia generic pharmacy network. While the company turned EBITDA positive on a YoY basis, margins were significantly squeezed sequentially to 0.89% due to high pre-opening costs for over 400 stores currently under development. The company added 276 stores during the quarter, bringing the total to 2,331, and successfully raised ₹350 crore via QIP to fund further expansion. Management maintains a long-term target of reaching 5,000 stores by March 2029.
முக்கிய அம்சங்கள்
Consolidated Revenue grew 98.2% YoY to ₹14,295.14 lakhs, with Davaindia sales jumping 150% YoY to ₹11,479.27 lakhs.Gross margins improved to 60.28% from 55.86% YoY, reflecting better scale and product mix.EBITDA turned positive at ₹127.58 lakhs compared to a loss of ₹556.47 lakhs in Q3FY25, though it fell sharply from Q2FY26 levels.Davaindia network expanded to 2,331 stores nationwide, with 276 new stores added in Q3FY26 alone.Successfully completed a ₹350 crore QIP to support the rollout of Company-Owned Company-Operated (COCO) stores.
👀 கவனிக்க வேண்டியவை
Investors should monitor the unit economics of the Davaindia stores as the company prioritizes rapid scale over immediate profitability. While the top-line growth is exceptional, the impact of pre-opening expenses on margins warrants a cautious approach until operating leverage kicks in.
Zota Health Care Q3 Revenue Surges 60% YoY; Approves 100% Acquisition of Curexis Ventures
Zota Health Care reported a strong standalone performance for Q3 FY26, with revenue growing 60% YoY to ₹108.88 crore and net profit rising to ₹6.01 crore. The Board has approved the 100% acquisition of Curexis Ventures Private Limited and a further investment in its subsidiary, Davaindia Health Mart Limited, via a rights issue. While standalone growth is robust, the consolidated financials are weighed down by significant losses from subsidiaries, which reported a net loss of ₹34.51 crore for the quarter. Investors should focus on the integration of the new acquisition and the path to profitability for the retail pharmacy segment.
முக்கிய அம்சங்கள்
Standalone revenue for Q3 FY26 grew 59.8% YoY to ₹108.88 crore from ₹68.13 crore.Standalone net profit for the quarter increased nearly 3x to ₹6.01 crore compared to ₹2.08 crore in the previous year.Board approved the 100% acquisition of Curexis Ventures Private Limited to expand its healthcare portfolio.Subsidiaries reported a combined net loss of ₹34.51 crore for the quarter, impacting overall consolidated performance.Company to subscribe to 58,827 equity shares of Davaindia Health Mart Limited via a rights issue to support its subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should monitor the turnaround progress of the Davaindia subsidiary as its losses are currently offsetting the strong standalone growth. The acquisition of Curexis Ventures is a key expansion move that warrants a watch on integration and synergy benefits.
Zota Health Care Q3 Standalone PAT Jumps 189% YoY; Board Approves Curexis Ventures Acquisition
Zota Health Care reported a strong standalone performance for Q3 FY26, with revenue rising 60% YoY to ₹108.88 crore and PAT surging to ₹6.01 crore. However, the consolidated outlook remains pressured as subsidiaries reported a combined net loss of ₹34.51 crore for the quarter. The company is actively expanding, approving the 100% acquisition of Curexis Ventures Private Limited and further capital infusion into its subsidiary, Davaindia Health Mart. A new Risk Management Committee has also been established to oversee the company's growing operational complexity.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations grew 59.8% YoY to ₹108.88 crore in Q3 FY26.Standalone Net Profit increased by 189% YoY, reaching ₹6.01 crore compared to ₹2.08 crore in the previous year.Board approved the 100% acquisition of Curexis Ventures Private Limited to strengthen market position.Subsidiaries contributed ₹77.44 crore to revenue but incurred a significant net loss of ₹34.51 crore during the quarter.Approved subscription to a rights issue for 58,827 equity shares of wholly-owned subsidiary Davaindia Health Mart Limited.
👀 கவனிக்க வேண்டியவை
Investors should weigh the impressive standalone growth against the heavy losses in the Davaindia subsidiary, which continue to drag down consolidated performance. Monitor the integration of Curexis Ventures and the timeline for subsidiary break-even before increasing exposure.
Zota Health Care Allots 1.79 Lakh Equity Shares on Warrant Conversion at Rs 509/Share
Zota Health Care has approved the allotment of 1,79,169 equity shares following the conversion of warrants by five non-promoter investors. The shares were issued at a price of Rs 509 each, resulting in a capital inflow of approximately Rs 6.84 crore through the receipt of 75% exercise money. This conversion has increased the company's total paid-up equity capital to Rs 34.06 crore. Currently, 5,71,961 warrants remain outstanding from the original preferential issue of 26.44 lakh warrants initiated in 2024.
முக்கிய அம்சங்கள்
Allotment of 1,79,169 equity shares at an issue price of Rs 509 per share (including Rs 499 premium)Total exercise money received from 5 non-promoter warrant holders amounts to Rs 6.84 crorePaid-up equity capital increased from 3,38,81,457 to 3,40,60,626 equity sharesRemaining outstanding warrants stand at 5,71,961 out of the original 26,44,836 allotted in August 2024
👀 கவனிக்க வேண்டியவை
Investors should note the minor equity dilution resulting from this conversion, which is part of a planned capital raise. Monitor the conversion of the remaining 5.71 lakh warrants as they will further impact the share count.
Zota's Davaindia Hits 2,331 Stores; Independent Study Validates 100% Generic Drug Quality
Zota Health Care's Davaindia chain has been validated by an independent MESH study, confirming 100% quality compliance across 131 generic medicines compared to branded equivalents. The company reported a total of 2,331 stores as of December 31, 2025, having added 276 stores in Q3 FY26 alone. Davaindia's business model offers 30-90% savings over branded drugs, attracting 16 lakh monthly customers with a high 80% repeat rate. Furthermore, the company has strengthened its capital position by raising ₹350 crore through a QIP.
முக்கிய அம்சங்கள்
Independent MESH study validates 100% quality compliance for Davaindia generics across 22 therapeutic categories.Total store network reached 2,331 outlets as of Dec 31, 2025, with 276 new stores added in Q3 FY26.Generic medicines priced 30% to 90% lower than branded equivalents across a portfolio of 2,000+ SKUs.Strong customer loyalty demonstrated by an 80% repeat purchase rate and 16 lakh monthly customers.Successfully raised ₹350 crore through a QIP to support nationwide expansion and working capital.
👀 கவனிக்க வேண்டியவை
The independent quality validation is a significant brand-building milestone that should help overcome consumer skepticism regarding generic medicines. Investors should monitor the execution of the new COCO stores and the utilization of QIP funds to drive further market share in the organized pharmacy retail space.
Zota Health Care to Invest Rs 170 Crore in Subsidiary Davaindia for Retail Expansion
Zota Health Care Limited has announced a significant investment of Rs 169.99 crores in its wholly-owned subsidiary, Davaindia Health Mart Limited (DIHML), via a rights issue. The funds are earmarked for the strategic expansion of Company Owned Company Operated (COCO) stores and to support working capital needs. DIHML has demonstrated impressive growth, with its turnover surging from Rs 14.61 crores in FY23 to Rs 109.93 crores in FY25. This move strengthens Zota's footprint in the generic pharmacy retail space, where it currently operates 1,438 stores.
முக்கிய அம்சங்கள்
Investment of Rs 169.99 crores through the acquisition of 3,95,348 shares at Rs 4,300 each.Davaindia's turnover increased significantly from Rs 14.61 Cr in FY23 to Rs 109.93 Cr in FY25.The subsidiary manages a network of 1,438 stores across 25 states and 5 Union Territories as of Dec 2025.Capital will be utilized for expanding the COCO store model and meeting operational requirements.
👀 கவனிக்க வேண்டியவை
This capital infusion highlights Zota's aggressive growth strategy in the high-potential generic medicine retail market. Investors should track the scaling of the COCO model and its contribution to overall consolidated profitability.
Zota Health Care Allots 1.07 Lakh Equity Shares on Warrant Conversion at Rs 509/share
Zota Health Care Limited has allotted 1,07,556 equity shares to three non-promoter investors upon the conversion of warrants. The conversion occurred at an issue price of Rs 509 per share, bringing in approximately Rs 4.11 crore in exercise money. This move has increased the company's total paid-up equity capital to Rs 33.88 crore. Currently, 7,51,130 warrants remain outstanding for future conversion within the 18-month window.
முக்கிய அம்சங்கள்
Allotment of 1,07,556 equity shares at Rs 509 per share including Rs 499 premiumReceipt of Rs 4.11 crore as 75% warrant exercise money from non-promoter groupTotal paid-up capital increased to Rs 33.88 crore from Rs 33.77 crore7,51,130 warrants remain outstanding from the original August 2024 issuance
👀 கவனிக்க வேண்டியவை
The conversion indicates investor confidence at the Rs 509 price point; however, shareholders should be aware of the gradual equity dilution as the remaining warrants are converted.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
